Drug Type TIL therapy |
Synonyms- |
Target |
Mechanism 4-1BB modulators(Tumor necrosis factor receptor superfamily member 9 modulators), CD2 modulators(Lymphocyte function antigen-3 receptor modulators), CD28 modulators(T-cell-specific surface glycoprotein CD28 modulators) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Preclinical | US | 05 Nov 2024 |